Developing story · 2 episodes · 20 Oct to 23 Oct
OpenAI Acquires Orchestra Bio For Drug Development
OpenAI is expanding its life sciences capabilities by acquiring Orchestra Bio to integrate AI coordination into drug development. The latest development confirms the acquisition aims to enhance Rosalind tools for orchestrating complex biological research workflows.
-
OpenAI acquires Orchestra Bio to add AI coordination for drug development
On October 20, 2026 OpenAI announced it had acquired Orchestra Bio, a platform that helps biopharmaceutical teams coordinate the many decisions and dependencies that follow drug discovery. The…
1 source -
OpenAI acquires Orchestra Bio to expand Rosalind life sciences tools
OpenAI announced on October 20, 2026, that it has acquired Orchestra Bio, a startup founded around 2022 that builds AI agents to help pharmaceutical companies manage drug development programs. The…
19 sources
Who and what